Neural Damage and Anesthetic Treatment in the Preeclamptic Parturient; a Prospective Observational Study.

Study Overview
=================
Brief Summary
-----------------
Objectives: Our primary objective is to evaluate the effect of anesthetic method (general versus regional anesthesia) on neural outcomes in the preeclamptic population undergoing cesarean delivery. Secondary outcome is to examine the fetal cerebral outcomes associated with the anesthetic method. Methodology: This prospective, observational study, will include 50 preeclamptic parturients undergoing cesarean section under general and regional anesthesia. Neuron specific enolase and S100B Protein are neuronal injury biomarkers. Increased levels of these biomarkers in serum indicate neuron damage. Following enrollment venous blood will be drawn from the participants and assessed for NSE and S100B serum levels at the following points; Upon hospital admission and one day postpartum. Furthermore in order to evaluate fetal outcomes upon fetal delivery, umbilical cord blood will be examined for NSE and S100B. Study significance: While spinal anesthesia is the preferred anesthetic method for the preeclamptic parturient undergoing cesarean delivery, it remains uncertain which anesthetic method is neuroprotective. This study will be the first study, to our knowledge, to examine the effect of anesthetic method on neuronal outcomes for a parturient with preeclampsia undergoing cesarean delivery, by the use of noninvasive cerebral biomarkers.

Detailed Description
-----------------
Scientific background: Preeclampsia is an idiopathic maternal, multi organ, specific pregnancy disorder, associated with significant maternal and perinatal morbidity and mortality. Preeclampsia complicates approximately 2-8% of all pregnancies. The disorder is characterized by new-onset of hypertension and proteinuria developing after gestational week 20. While the pathogenesis of the disease remains not completely understood, a possible explanation is endothelial cell dysfunction in which placenta-derived mediators causes multisystem organ dysfunction . Preeclampsia increases the risk for acute cerebrovascular complications such as intracerebral hemorrhage, cerebral edema and eclampsia. Treatment with magnesium sulfate reduces the risk for seizures and treatment with antihypertensive therapy reduces the risk for a stroke , however the only effective treatment for the syndrome is prompt delivery of the fetus . When considering the optimal anesthetic method for a preeclamptic parturient undergoing cesarean delivery, neuraxial anesthetic techniques, when feasible, are strongly preferred to general anesthesia (GA) . Spinal anesthesia (SA) is favored over general anesthesia since it is associated with increased benefits and reduced risks compared with general anesthesia. Increased benefits of SA include higher patient satisfaction, decreased pain and favorable neonatal outcomes. GA has been associated with increased risk for aspiration, unstable hemodynamics and difficult airway management . In addition GA has been shown to increase the risk for a stroke in women with preeclampsia . Nevertheless GA is sometime used in the preeclamptic parturient due to maternal or fetal indications with an incidence as high as 44% in some European countries . Accumulative evidence from animal studies indicate that general anesthetic agents are neurotoxic and can induce subsequent behavioral abnormalities in the developmental mind . However the fetal and pediatric implications remain inconclusive. In a population-based birth cohort study fetal exposure to general anesthesia during cesarean delivery was not associated with increased risk for learning disabilities compared to delivering vaginally . In contrast in a population-based birth cohort study conducted in Taiwan the incidence of autism was increased in neonates who were delivered by cesarean delivery under general anesthesia compared with regional anesthesia . Despite experts favoring neuraxial anesthesia for the preeclamptic population, to date research remains inconclusive regarding which anesthetic method is neuroprotective. In recent years numerous biochemical tests have become usual clinical cerebral damage biomarkers, amongst them is the Neuron specific enolase (NSE). The NSE is an intracytoplasmic glycolytic enzyme enolase . The enzyme is expressed in neurons and neuroendocrine tissue . Increased levels of NSE are released into the blood circulation according to the death rate of those cells . Elevated levels of NSE have been observed after severe head trauma and in association to postoperative cognitive dysfunction . S100B Protein, an additional neuronal injury biomarker, is an acidic calcium-binding protein, and physiological serum levels of S100B protein are low . The protein is found primarily in astrocytes and Schwann cells and has both intracellular and extracellular targets. Elevated serum and CSF levels of S100B indicate neural damage . Research evaluating cerebral damage biomarkers in parturients with preeclampsia has found increased levels of neuronal injury biomarkers compared with healthy parturients . Furthermore increased plasma levels of S100B have been correlated with neurological symptoms in the form of visual disturbances . Lisa et al demonstrated persistent increased levels of NSE up to one year postpartum . Additionally, various studies have examined the correlation between cerebral biomarkers levels in umbilical cord blood, amniotic fluid and fetal pathological conditions: intra uterine fetal death, preterm delivery, cerebral palsy and preeclampsia . Tskitishvili, et al showed increased levels of cerebral injury damage in amniotic fluid of parturients with preeclampsia . In this study we aim to evaluate the effect of anesthetic method on neural outcomes in the preeclamptic population undergoing cesarean delivery. Specific Aims: Our primary objective is to examine which anesthetic method (GA versus RA) is associated with reduced neural damage as measured by NSE and S100B serum levels in preeclamptic parturients undergoing cesarean delivery. Our secondary objective is to examine the effect of anesthetic method on fetal cerebral outcomes as measured by NSE and S100B umbilical cord blood levels in parturients with preeclampsia. Study Design: This is a prospective, single center, observational trial to assess the effect of anesthetic method on cerebral outcomes. The study will be conducted at the Rabin Medical Center (Beilinson Campus), Petach Tikva, Israel, a tertiary university hospital. Fifty preeclamptic parturients aged 18 and above, undergoing cesarean delivery under SA or GA, will be included in the study. This study is a purely observational study, it will not have any clinical intervention nor will it interfere with standard cesarean delivery protocols in any way. Inclusion criteria Fifty preeclamptic parturients age 18 and above presenting for cesarean delivery under SA or GA, with ability to comply with study requirements will be enrolled in the study. Exclusion criteria The following parturients will be excluded: Parturients under age 18 Parturients undergoing a vaginal delivery. Parturients unable to sign an informed consent forum. Study enrollment: All preeclamptic parturients will be recruited upon admission to the women's emergency room. All participating patients will undergo an informed consent process, which will include a through explanation of the study design and patient requirements, by the study investigator. Following which patients will be requested to sign the informed consent document. Index procedure: Following obtaining approval from parturients 5 cc of venous blood will be drawn from each of the participants and will be examined for NSE and S100B serum levels at the following time points: Upon hospital admission following obtaining informed consent approval. Upon fetal delivery, umbilical cord blood will be examined for NSE and S100B. 1 day postpartum. The blood samples will be collected in heparin containing tubes, the samples will be kept in room temperature for no longer than an hour before being sent to the laboratory for centrifugation. Following centrifugation the samples will be frozen at -70 °C until levels of NSE and S100B can be analyzed. Plasma levels will be tested to detect NSE and S100B levels using commercially available kits (Liasion Sangtec 100) according to the manufacturer's recommendations. Intraoperative anesthetic technique will be administered at anesthesiologists' discretion. The study cohort will be divided into two groups: women undergoing cesarean delivery under general anesthesia, and women undergoing cesarean delivery under regional-spinal anesthesia. NSE and S100B levels will be compared for both groups in order to evaluate which anesthetic method is associated with reduced neuronal injury Additionally, umbilical cord blood NSE and S100B levels will be compared for both groups, in order to assess the fetal outcomes of each anesthetic method. Data collection: For each participant the following additional data will be collected and documented: Demographic data obstetric age, weight, height, Obstetric data; gravidity and parity, obstetric history comorbidities, regular medication and preeclampsia management protocols and more. Anesthetic and analgesic data: type of anesthesia / analgesia, anesthetic drug solution, anesthetic drug doses, vasopressor treatment, hemodynamic data, and other anesthetic data.

Official Title
-----------------
Neural Damage and Anesthetic Treatment in the Preeclamptic Parturient; a Prospective Observational Cohort Study.

Conditions
-----------------
Phosphopyruvate Hydratase

Intervention / Treatment
-----------------
* Biological: Neuron specific enolase (NSE)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Fifty preeclamptic parturients age 18 and above presenting for cesarean delivery under SA or GA, with ability to comply with study requirements will be enrolled in the study. Exclusion Criteria: The following parturients will be excluded: Parturients under age 18 Parturients undergoing a vaginal delivery. Parturients unable to sign an informed consent forum.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
Female

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Women undergoing cesarean delivery with general anesthesia<br>Preeclamptic parturients undergoing cesarean delivery under general anesthesia | Biological: Neuron specific enolase (NSE)<br>* 5 cc of venous blood will be drawn from all of the participants and be examined for NSE and S100 B serum levels in order to evaluate evaluate which anesthetic method (general anesthesia versus spinal anesthesia) is associated with reduced neuronal injury in a preeclamptic parturients undergoing a cesarean section.<br>* Other names: S100B Protein;|
| Women undergoing cesarean delivery with spinal anesth<br>Preeclamptic parturients undergoing cesarean delivery under regional-spinal anesthesia | Biological: Neuron specific enolase (NSE)<br>* 5 cc of venous blood will be drawn from all of the participants and be examined for NSE and S100 B serum levels in order to evaluate evaluate which anesthetic method (general anesthesia versus spinal anesthesia) is associated with reduced neuronal injury in a preeclamptic parturients undergoing a cesarean section.<br>* Other names: S100B Protein;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| NSE serum levels | Maternal serum NSE levels after delivery in both study groups | 1 Day postpartum | 
| S100 B protein | Maternal serum S100B levels after delivery in both study groups. Maternal serum NSE levels after delivery in both study groups | 1 Day postpartum | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Fetal serum NSE levels | Umbilical cord serum NSE levels | At delivery | 
| Fetal serum S100b levels | Umbilical cord serum S100b levels | At delivery |